Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
161 participants
OBSERVATIONAL
2010-12-31
2017-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ethnic/Racial Differences in Metabolism and DNA Adduct Formation
NCT03421678
DNA Repair and Genetic Susceptibility to Lung Cancer
NCT00611598
Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States
NCT00340457
Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer
NCT00898313
Genetic Susceptibility to Lung Cancer in Never Smokers
NCT00597636
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Tobacco-specific nitrosamines (TSNA) are among the most significant carcinogens in tobacco products. Multiple international studies clearly document the occurrence of substantial amounts of these carcinogens in both unburned tobacco and tobacco smoke. One of the most prevalent of these compounds, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), is present in both unburned tobacco and cigarette smoke, and is a remarkably effective lung carcinogen in laboratory animals, inducing lung tumors in rodents independent of the route of administration. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a metabolite of NNK, is also a pulmonary carcinogen. NNK has been classified by the International Agency for Research on Cancer as a Group 1 carcinogen (carcinogenic to humans). Consistent with this, 2 recent studies by our group have demonstrated that levels of NNAL in serum or urine are related to lung cancer in smokers.
Our primary aim is to conduct a comprehensive analysis of urinary biomarkers of NNK metabolic activation and detoxification in African American and European American smokers. We hypothesize that, after adjustment for smoking level, the relative contribution of the biomarkers of NNK metabolic activation to the total amount of NNK metabolites will be higher in African Americans as compared to European Americans. Our secondary aim is to measure in exfoliated oral mucosa cells of African American and European American smokers DNA adducts formed as a result of NNK metabolic activation. The results of these measurements will offer a direct measure of NNK-induced DNA damage in smokers, and will be critical to an understanding of the balance between the urinary excretion of NNK metabolites and the extent of NNK DNA binding. We hypothesize that African Americans will have in the DNA of their oral mucosa cells higher levels of NNK-derived DNA adducts as compared to European Americans. Finally, we will investigate the relationship between levels of NNK-derived DNA adducts measured in oral mucosa cells and the rates of repair of these adducts in cultured lymphocytes from our subjects. These measurements will allow us to evaluate more fully the role of variations in NNK metabolism in the observed differences in lung cancer risk between European American and African American smokers. We expect that that African Americans will have lower capacity to repair NNK-induced DNA damage as compared to European Americans, and this will correlate with higher levels of NNK-derived buccal DNA adducts.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
African Americans
Subjects will be classified as African American if they report themselves, biological parents and both sets of biological grandparents as African American or African descent.
No interventions assigned to this group
European American
Subjects will be classified as European American if they report themselves, biological parents and both sets of biological grandparents as European American or European descent.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects report themselves, biological parents and both sets of biological grandparents as
* African American or African descent or
* European American or European descent
3. Subjects are in apparently good physical health (no unstable medical condition)
4. Subjects are in stable, good mental health (e.g. not currently, within the past 6 months, experiencing unstable or untreated psychiatric diagnosis, including substance abuse, as determined by the PRIME-MD);
5. Subjects have provided written informed consent to participate in the study.
Exclusion Criteria
2. Cannot or unwilling to identify ethnic/racial ancestry
3. Women who are currently pregnant or breast feeding
4. Currently using any other tobacco or nicotine-containing product
5. Currently taking any medications that affect relevant metabolic enzymes.
21 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Masonic Cancer Center, University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dorothy K Hatsukami, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tobacco Research Programs University of Minnesota
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010NTLS056
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.